Ace Pharmaceuticals has been acquired by Gilde Buy Out Partners, Gilde Healthcare and Quadrum Capital

Ace Pharmaceuticals BV has been acquired by Gilde Buy Out Partners, Gilde Healthcare, Quadrum Capital and the management team.

Ace Pharmaceuticals is a leading pharmaceutical company in the niche of medical need products, and is based in Zeewolde, the Netherlands. As an independent company, Ace focuses on the development, production and distribution of licensed and unlicensed medicines. With its activities, Ace meets an essential social need: making and keeping scarce medication available for people for whom it is essential. It does so by actively collaborating with relevant stakeholders, including patient associations, doctors and governmental institutions. Since January 2020, Ace has also been supplying pharmaceutical compounding products to pharmacies in the Netherlands through its business unit Ace Compounding.

Oaklins’ debt advisory team in the Netherlands acted as advisor to the consortium and assisted in establishing a financing package aligned with the current business profile and future growth ambitions.

Uppdrag

Kapitalanskaffning, finansiering och ECM

Parter

“The COVID-19 pandemic has clearly highlighted the challenges and gaps in our industry in Europe. It makes our mission to make scarce medicines available more important than ever. We want to respond to this situation strongly by growing organically as well as through acquisitions in Europe. With the capital, the know-how and the broad (international) network of Gilde Buy Out Partners, Gilde Healthcare, and our existing investor Quadrum Capital, we can achieve this in both a socially responsible as well as financially sound manner.”

Jan Willem Popma

Director, Ace Pharmaceuticals BV

Prata med transaktionsteamet

Bas Stoetzer

Partner

Amsterdam, Nederländerna
Oaklins Netherlands

Se profil Kontakta oss

Niels Vermuë

Associate Director

Amsterdam, Nederländerna
Oaklins Netherlands

Se profil Kontakta oss

Relaterade transaktioner

Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.

Hälsovård

Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.

NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.

Lär dig mer

Groupe JVS has completed an LBO with Capza and Bpifrance

Riskkapital | TMT

Groupe JVS has completed an LBO with Capza and Bpifrance

The shareholders of Groupe JVS have completed an LBO with Capza and BpiFrance. Parquest sold their shares after partnering with the organization for three years. Groupe JVS’s management team will increase its ownership and remain as the majority shareholder of the group, alongside CAPZA and Bpifrance.

Lär dig mer

Creo Medical Group plc has completed a US$15.7 million equity fundraise

Hälsovård

Creo Medical Group plc has completed a US$15.7 million equity fundraise

Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.

Lär dig mer